The Volente Difference
•
0 likes•212 views
This document describes several panels for rapid molecular testing of infectious diseases from a single specimen, including a respiratory pathogen panel, gastrointestinal panel, urinary tract infection/sexually transmitted infection panel, and wound care panel. It highlights benefits such as next-day results, detection of difficult to culture pathogens, identification of antibiotic resistance mechanisms, and assistance with antimicrobial stewardship programs. The company presents itself as a leader in molecular diagnostics providing actionable patient-centered reporting and pharmacy medication review.
Report
Share
Report
Share
Download to read offline
Recommended
Volente Dx: Leaders in Rapid Molecular Pathology
Volente Diagnostics uses quantitative real-time PCR technology to identify pathogens from specimens with over 99.8% accuracy. Their panels can detect respiratory, gastrointestinal, wound, urinary tract, and sexually transmitted infections as well as antibiotic resistance. Results are available within 24 hours and provide information on pathogens present at low, moderate, or high levels. Reports include detected results, comprehensive test results, and antibiotic resistance results with treatment recommendations.
Urology Presentation
This document discusses advanced next-generation DNA sequencing techniques for identifying bacteria, fungi, and viruses. It highlights how DNA sequencing can identify over 13,000 pathogen DNA codes and is not affected by transport or culture issues. Examples are given where DNA sequencing identified chronic infections that cultures failed to detect. The document emphasizes how biofilms are difficult to culture but can be identified by DNA sequencing, and are responsible for 80% of infections. It provides examples comparing DNA sequencing to traditional cultures for identifying pathogens in chronic wounds and urine samples. The document also discusses using DNA diagnostic tests to provide treatment recommendations like customized topical therapies and antibiograms.
Multi Specialty Presentation
This document discusses a study that used next-generation DNA sequencing to analyze the microbiome of neuropathic diabetic foot ulcers. The study found that DNA sequencing identified more bacterial diversity in the ulcers than traditional cultures. DNA sequencing also showed higher microbial loads in the ulcers compared to cultures. This demonstrates that cultures underrepresent the true bacteria present in chronic wounds like diabetic foot ulcers. The study provides support for using molecular diagnostic approaches like DNA sequencing rather than solely relying on traditional cultures to identify bacteria in chronic wounds.
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
The document provides an overview of HIV/AIDS vaccine research and development efforts. It discusses the global impact of HIV/AIDS, the need for an effective vaccine, the various phases of vaccine development and testing, different vaccine candidates currently being tested including peptide epitopes, viral proteins, and viral vectors, as well as some of the large phase 2 and 3 clinical trials underway. It emphasizes that developing a safe and effective HIV vaccine will require a global collaborative effort.
Recent Advances in Management of Gram Negative Bacteria
This document discusses recent advances in treating multidrug-resistant gram-negative bacteria. It mentions that antimicrobial resistance is a global health problem and new antibiotics are urgently needed. It then summarizes recent developments in beta-lactam antibiotics like cephalosporins, carbapenems, and monobactams. Newer cephalosporins discussed include cefiderocol and cefepime/AAI101, which are undergoing clinical trials. Ceftobiprole is another newer cephalosporin marketed in Europe. Sulopenem is a novel oral and IV penem antibiotic in development.
HIV vaccines
The development of an HIV vaccine faces significant challenges including viral diversity, establishment of viral reservoirs, and immune evasion. Current vaccine strategies aim to elicit broadly neutralizing antibodies or enhance cellular immunity through various approaches including recombinant proteins, viral vectors, and DNA vaccines. While two vaccine concepts have undergone efficacy trials, neither provided protective effects. Ongoing research continues through clinical trials evaluating prime-boost regimens combining DNA vaccines and viral vectors.
Cefiderocol - Dr. ANCY GEORGE
Cefiderocol is a novel siderophore cephalosporin antibiotic being developed for the treatment of infections caused by carbapenem-resistant Gram-negative bacteria. A phase 2 clinical trial found intravenous cefiderocol to be non-inferior to imipenem-cilastatin for treating complicated urinary tract infections caused by multidrug-resistant Gram-negative pathogens. Cefiderocol utilizes bacterial iron transport systems to penetrate the outer membrane of Gram-negative bacteria and is highly stable against various carbapenemase enzymes. Its pharmacokinetics and safety profile support a dosage of 2g administered intravenously every 8 hours. These results provide a basis for submitting cefiderocol for FDA approval to treat serious Gram-negative
HIV Vaccine Development Strategies
This document summarizes different strategies for developing an HIV vaccine, outlining the challenges and current state of different vaccine types. It discusses how vaccines could potentially prevent or treat HIV infection, and highlights the obstacles like HIV's ability to mutate and target immune cells. Different vaccine types currently in clinical trials are described, including peptides, DNA, live vectors, and recombinant proteins. The largest vaccine trial to date, AIDSVAX, is summarized as stimulating antibodies but not proving effective against HIV.
Recommended
Volente Dx: Leaders in Rapid Molecular Pathology
Volente Diagnostics uses quantitative real-time PCR technology to identify pathogens from specimens with over 99.8% accuracy. Their panels can detect respiratory, gastrointestinal, wound, urinary tract, and sexually transmitted infections as well as antibiotic resistance. Results are available within 24 hours and provide information on pathogens present at low, moderate, or high levels. Reports include detected results, comprehensive test results, and antibiotic resistance results with treatment recommendations.
Urology Presentation
This document discusses advanced next-generation DNA sequencing techniques for identifying bacteria, fungi, and viruses. It highlights how DNA sequencing can identify over 13,000 pathogen DNA codes and is not affected by transport or culture issues. Examples are given where DNA sequencing identified chronic infections that cultures failed to detect. The document emphasizes how biofilms are difficult to culture but can be identified by DNA sequencing, and are responsible for 80% of infections. It provides examples comparing DNA sequencing to traditional cultures for identifying pathogens in chronic wounds and urine samples. The document also discusses using DNA diagnostic tests to provide treatment recommendations like customized topical therapies and antibiograms.
Multi Specialty Presentation
This document discusses a study that used next-generation DNA sequencing to analyze the microbiome of neuropathic diabetic foot ulcers. The study found that DNA sequencing identified more bacterial diversity in the ulcers than traditional cultures. DNA sequencing also showed higher microbial loads in the ulcers compared to cultures. This demonstrates that cultures underrepresent the true bacteria present in chronic wounds like diabetic foot ulcers. The study provides support for using molecular diagnostic approaches like DNA sequencing rather than solely relying on traditional cultures to identify bacteria in chronic wounds.
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
The document provides an overview of HIV/AIDS vaccine research and development efforts. It discusses the global impact of HIV/AIDS, the need for an effective vaccine, the various phases of vaccine development and testing, different vaccine candidates currently being tested including peptide epitopes, viral proteins, and viral vectors, as well as some of the large phase 2 and 3 clinical trials underway. It emphasizes that developing a safe and effective HIV vaccine will require a global collaborative effort.
Recent Advances in Management of Gram Negative Bacteria
This document discusses recent advances in treating multidrug-resistant gram-negative bacteria. It mentions that antimicrobial resistance is a global health problem and new antibiotics are urgently needed. It then summarizes recent developments in beta-lactam antibiotics like cephalosporins, carbapenems, and monobactams. Newer cephalosporins discussed include cefiderocol and cefepime/AAI101, which are undergoing clinical trials. Ceftobiprole is another newer cephalosporin marketed in Europe. Sulopenem is a novel oral and IV penem antibiotic in development.
HIV vaccines
The development of an HIV vaccine faces significant challenges including viral diversity, establishment of viral reservoirs, and immune evasion. Current vaccine strategies aim to elicit broadly neutralizing antibodies or enhance cellular immunity through various approaches including recombinant proteins, viral vectors, and DNA vaccines. While two vaccine concepts have undergone efficacy trials, neither provided protective effects. Ongoing research continues through clinical trials evaluating prime-boost regimens combining DNA vaccines and viral vectors.
Cefiderocol - Dr. ANCY GEORGE
Cefiderocol is a novel siderophore cephalosporin antibiotic being developed for the treatment of infections caused by carbapenem-resistant Gram-negative bacteria. A phase 2 clinical trial found intravenous cefiderocol to be non-inferior to imipenem-cilastatin for treating complicated urinary tract infections caused by multidrug-resistant Gram-negative pathogens. Cefiderocol utilizes bacterial iron transport systems to penetrate the outer membrane of Gram-negative bacteria and is highly stable against various carbapenemase enzymes. Its pharmacokinetics and safety profile support a dosage of 2g administered intravenously every 8 hours. These results provide a basis for submitting cefiderocol for FDA approval to treat serious Gram-negative
HIV Vaccine Development Strategies
This document summarizes different strategies for developing an HIV vaccine, outlining the challenges and current state of different vaccine types. It discusses how vaccines could potentially prevent or treat HIV infection, and highlights the obstacles like HIV's ability to mutate and target immune cells. Different vaccine types currently in clinical trials are described, including peptides, DNA, live vectors, and recombinant proteins. The largest vaccine trial to date, AIDSVAX, is summarized as stimulating antibodies but not proving effective against HIV.
Malarial vaccine
The document discusses malaria, which infects hundreds of millions annually and kills over 1 million people per year, mostly in Africa. It outlines the challenges in developing an effective malaria vaccine, including the parasite's ability to evade the immune system and lack of animal models for testing. Several past and current vaccine candidates are mentioned, including SPf66 (the first field trial vaccine), RTS,S (the most advanced candidate to date), and PfSPZ Vaccine (a whole parasite vaccine showing promise in recent trials). Overall, the document reviews the state of malaria vaccine research and the hurdles remaining in developing a highly effective vaccine.
Ebola virus disease in the democratic republic of Congo{
The EVD outbreak in the DRC has clinical and epidemiologic characteristics that are similar to those of previous EVD outbreaks in equatorial Africa.
The causal agent is a local EBOV variant, and this outbreak has a zoonotic origin different from that in the 2014 epidemic in West Africa.
Recent outbreak of diseases related to humans.
Recently we have faced many outbreak of human diseases throughout the world, one of them being COVID-19. This presentation gives a detailed information about these outbreaks. Main focus is on COVID-19 as it is the prevailing outbreak.
Current status of Malaria vaccine (Nov 2016)
This document summarizes information about the current status of malaria vaccines. It discusses the burden of malaria worldwide and in India. It describes the life cycle of Plasmodium parasites and the different types of malaria. The key targets for malaria vaccines including pre-erythrocytic, blood stage, and transmission blocking vaccines are outlined. The currently available RTS,S vaccine is described including results from phase 3 trials showing moderate efficacy that wanes over time. Challenges in developing effective malaria vaccines are discussed such as applying traditional vaccine approaches, limitations of animal models, and waning vaccine efficacy. New malaria vaccine projects in India including JAIVAC-1 and JAIVAC-2 are briefly introduced.
Malaria vaccine
A malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections and has a relatively low efficacy.
HIV Vaccine
Over 60 million people have been infected with HIV since 1981, and 39.5 million people are currently living with HIV. There are still around 4.3 million new infections each year, and over 28 million people have died of AIDS-related illnesses since the start of the pandemic. Developing an effective HIV vaccine has proven extremely challenging due to the virus's ability to mutate and evade the immune system. While several vaccine candidates have reached clinical trials, none have yet provided reliable, long-term sterilizing immunity. Continued research efforts aim to develop a vaccine that can eliminate HIV infections and end the pandemic.
HUMAN IMMUNODEFICIENCY VIRUS/HIV
The document discusses World AIDS Day which is held annually on December 1st to raise awareness about HIV/AIDS and show support for those living with the disease. It provides information about the themes, transmission, stages of HIV infection, testing, and treatment. The document also outlines the goals of increasing HIV testing and treatment to work towards eliminating HIV/AIDS by 2030.
Sars co v-2 vaccines
The document discusses the development of vaccines for SARS-CoV-2. It outlines the strategies being tested, including RNA, DNA, recombinant protein, and vectored vaccines. Clinical trials are underway to test remdesivir, lopinavir/ritonavir, and antibodies from recovered patients. Lessons from SARS-CoV-1 and MERS-CoV vaccines indicate the spike protein is a target, but development faces challenges like inducing long-term immunity and protecting older individuals. The production process requires efficacy and safety testing which can prolong time to widespread availability.
9 Malaria Vaccine (1)
MVI is working with ICGEB in India to develop a vaccine against Plasmodium vivax. This effort includes Bharat Biotech, which will manufacture the vaccine for preclinical and initial safety trials in adults. The vaccine aims to prevent infection, decrease infection intensity, and prevent malaria transmission.
Pathogen discovery platform
This document summarizes a metagenomics and zoonotic pathogen discovery platform. It developed highly multiplexed sequencing techniques that reduced costs. Using samples from wildlife, livestock, humans and vectors, it identified several viruses in East Africa, including Rift Valley Fever virus, and developed diagnostic tools. Over 250 pathogen sequences were submitted to gene banks. The platform aims to enhance disease surveillance and control in Africa through early detection, which can reduce animal losses and improve food security, health and incomes. Future work includes expanded surveillance, utilizing developed diagnostic tools, and new collaborations.
Prof. anzala hiv vaccine update
The document outlines research being conducted at KAVI-ICR on HIV vaccine development. It discusses current global progress including some vaccines that showed efficacy and others that did not. KAVI is conducting several phase 1 clinical trials of vaccine candidates alone or in prime-boost combinations. The goal is to advance candidates that elicit broadly neutralizing antibodies or durable cellular immune responses to control HIV infection. Challenges include HIV's variability, but replicating viral vectors and designing immunogens to target specific sites on HIV show promise.
Malaria vaccine
Basic concepts of malaria vaccine
and various vaccines in pipeline along with recently approved vaccine.
Advanced diagnostics of tuberculosis 21 3-15
Recent advances in the diagnosis of tuberculosis include molecular methods that can rapidly detect Mycobacterium tuberculosis and resistance to rifampicin. The Xpert MTB/RIF assay can detect M. tuberculosis and rifampicin resistance directly from sputum samples in less than one day, which is much faster than traditional solid or liquid culture methods requiring weeks. Meta-analyses show the Xpert MTB/RIF assay has high sensitivity and specificity for detecting rifampicin resistance. While a major improvement, the Xpert MTB/RIF assay is still being evaluated for use with extra-pulmonary samples which typically yield lower sensitivity. Rapid molecular diagnostics are transforming tuberculosis diagnosis and treatment monitoring.
Antimicrobial resistance for clinicians
Slide from WHO CME ITALIAN COURSE
Antimicrobial resistance for clinicians
Core competencies for antimicrobial prescribing:
Understands the patient and the patient’s clinical needs
Understands treatment options and how they support the
patient’s clinical needs
Works in partnership with the patient and other healthcare
professionals to develop and implement a treatment plan
Communicates the treatment plan and its rationale clearly to
the patient and other health professionals
Monitors and reviews the patient’s response to treatment
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
The document discusses the manufacturing process for COVID-19 vaccines. It describes the traditional vaccine development process which uses weakened pathogens versus the novel mRNA vaccine process used for COVID-19 vaccines which uses genetic code to produce antigens. The manufacturing process for vaccines involves fermentation, purification, formulation, filling and packaging. Challenges in developing COVID-19 vaccines include limited worldwide distribution due to cold chain requirements, lack of long term safety and efficacy data for novel mRNA vaccines, and ensuring proper vaccine administration to stimulate immunity.
Re-purposing ILRI labs to support national COVID-19 testing in Kenya
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
Recent advances in malaria
This document summarizes recent advances in malaria diagnosis, treatment, vaccines, and elimination efforts. It describes new diagnostic techniques like rapid diagnostic tests and molecular methods like PCR. It outlines recent treatment advances like new artemisinin-based combination therapies and injectable artesunate for severe malaria. It discusses the RTS,S malaria vaccine and new highly effective vaccine candidates in clinical trials. It also summarizes global strategies and targets for malaria elimination by 2030 through efforts like the WHO Global Malaria Programme, genetic research with MalariaGEN, and novel approaches like gene drive modified mosquitoes to reduce disease transmission.
SUPERBUGS , NEW HOPE NEW ANTIBIOTICS
This document summarizes new and emerging antibiotic treatments for multi-drug resistant bacteria, or "superbugs". It discusses several new classes of antibiotics targeting both Gram-positive and Gram-negative bacteria, including new cephalosporins, lipoglycopeptides, lipopeptides, streptogramins, carbapenems, and glycylcyclines. Concerns are raised about increasing antibiotic resistance and the lack of new antibiotic development, as well as the need to target emerging threats from multi-drug resistant Gram-negative bacteria.
MDR-TB
This document discusses multi-drug resistant tuberculosis (MDR TB). It begins with an introduction to TB and definitions of key terms like MDR and XDR TB. It then describes first and second line anti-TB drugs, mechanisms of drug resistance, and factors contributing to acquired resistance. The document outlines methods for diagnosing drug resistance including genetic detection and drug sensitivity testing. It concludes with a brief overview of treatment approaches for MDR TB.
Vish Nene - Building back better: How can public food and agricultural resear...
Vish Nene - Building back better: How can public food and agricultural resear...International Food Policy Research Institute (IFPRI)
POLICY SEMINAR
Virtual Event - Building back better: How can public food and agricultural research institutions be strengthened and rebuilt after the COVID-19 pandemic?
Co-Organized by IFPRI and the International Consortium on Applied Bioeconomic Research (ICABR)
FEB 2, 2021 - 09:30 AM TO 11:00 AM ESTAntibiotic stewardship by dr praman
1) Antimicrobial stewardship programs aim to optimize antibiotic use and prevent resistance by coordinating actions to improve prescribing. They promote appropriate use through guidelines, education, and monitoring of antibiotic use and outcomes.
2) In NICUs, antimicrobial stewardship faces unique challenges due to non-specific signs of infection in neonates and difficulties obtaining cultures. Programs seek to minimize broad-spectrum antibiotic exposure and duration to reduce resistance and side effects.
3) Effective strategies for neonatal antimicrobial stewardship include developing unit-specific treatment guidelines, prospectively auditing antibiotic use, educating providers, streamlining therapy based on culture results, and implementing bundles to prevent infections.
More Related Content
What's hot
Malarial vaccine
The document discusses malaria, which infects hundreds of millions annually and kills over 1 million people per year, mostly in Africa. It outlines the challenges in developing an effective malaria vaccine, including the parasite's ability to evade the immune system and lack of animal models for testing. Several past and current vaccine candidates are mentioned, including SPf66 (the first field trial vaccine), RTS,S (the most advanced candidate to date), and PfSPZ Vaccine (a whole parasite vaccine showing promise in recent trials). Overall, the document reviews the state of malaria vaccine research and the hurdles remaining in developing a highly effective vaccine.
Ebola virus disease in the democratic republic of Congo{
The EVD outbreak in the DRC has clinical and epidemiologic characteristics that are similar to those of previous EVD outbreaks in equatorial Africa.
The causal agent is a local EBOV variant, and this outbreak has a zoonotic origin different from that in the 2014 epidemic in West Africa.
Recent outbreak of diseases related to humans.
Recently we have faced many outbreak of human diseases throughout the world, one of them being COVID-19. This presentation gives a detailed information about these outbreaks. Main focus is on COVID-19 as it is the prevailing outbreak.
Current status of Malaria vaccine (Nov 2016)
This document summarizes information about the current status of malaria vaccines. It discusses the burden of malaria worldwide and in India. It describes the life cycle of Plasmodium parasites and the different types of malaria. The key targets for malaria vaccines including pre-erythrocytic, blood stage, and transmission blocking vaccines are outlined. The currently available RTS,S vaccine is described including results from phase 3 trials showing moderate efficacy that wanes over time. Challenges in developing effective malaria vaccines are discussed such as applying traditional vaccine approaches, limitations of animal models, and waning vaccine efficacy. New malaria vaccine projects in India including JAIVAC-1 and JAIVAC-2 are briefly introduced.
Malaria vaccine
A malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections and has a relatively low efficacy.
HIV Vaccine
Over 60 million people have been infected with HIV since 1981, and 39.5 million people are currently living with HIV. There are still around 4.3 million new infections each year, and over 28 million people have died of AIDS-related illnesses since the start of the pandemic. Developing an effective HIV vaccine has proven extremely challenging due to the virus's ability to mutate and evade the immune system. While several vaccine candidates have reached clinical trials, none have yet provided reliable, long-term sterilizing immunity. Continued research efforts aim to develop a vaccine that can eliminate HIV infections and end the pandemic.
HUMAN IMMUNODEFICIENCY VIRUS/HIV
The document discusses World AIDS Day which is held annually on December 1st to raise awareness about HIV/AIDS and show support for those living with the disease. It provides information about the themes, transmission, stages of HIV infection, testing, and treatment. The document also outlines the goals of increasing HIV testing and treatment to work towards eliminating HIV/AIDS by 2030.
Sars co v-2 vaccines
The document discusses the development of vaccines for SARS-CoV-2. It outlines the strategies being tested, including RNA, DNA, recombinant protein, and vectored vaccines. Clinical trials are underway to test remdesivir, lopinavir/ritonavir, and antibodies from recovered patients. Lessons from SARS-CoV-1 and MERS-CoV vaccines indicate the spike protein is a target, but development faces challenges like inducing long-term immunity and protecting older individuals. The production process requires efficacy and safety testing which can prolong time to widespread availability.
9 Malaria Vaccine (1)
MVI is working with ICGEB in India to develop a vaccine against Plasmodium vivax. This effort includes Bharat Biotech, which will manufacture the vaccine for preclinical and initial safety trials in adults. The vaccine aims to prevent infection, decrease infection intensity, and prevent malaria transmission.
Pathogen discovery platform
This document summarizes a metagenomics and zoonotic pathogen discovery platform. It developed highly multiplexed sequencing techniques that reduced costs. Using samples from wildlife, livestock, humans and vectors, it identified several viruses in East Africa, including Rift Valley Fever virus, and developed diagnostic tools. Over 250 pathogen sequences were submitted to gene banks. The platform aims to enhance disease surveillance and control in Africa through early detection, which can reduce animal losses and improve food security, health and incomes. Future work includes expanded surveillance, utilizing developed diagnostic tools, and new collaborations.
Prof. anzala hiv vaccine update
The document outlines research being conducted at KAVI-ICR on HIV vaccine development. It discusses current global progress including some vaccines that showed efficacy and others that did not. KAVI is conducting several phase 1 clinical trials of vaccine candidates alone or in prime-boost combinations. The goal is to advance candidates that elicit broadly neutralizing antibodies or durable cellular immune responses to control HIV infection. Challenges include HIV's variability, but replicating viral vectors and designing immunogens to target specific sites on HIV show promise.
Malaria vaccine
Basic concepts of malaria vaccine
and various vaccines in pipeline along with recently approved vaccine.
Advanced diagnostics of tuberculosis 21 3-15
Recent advances in the diagnosis of tuberculosis include molecular methods that can rapidly detect Mycobacterium tuberculosis and resistance to rifampicin. The Xpert MTB/RIF assay can detect M. tuberculosis and rifampicin resistance directly from sputum samples in less than one day, which is much faster than traditional solid or liquid culture methods requiring weeks. Meta-analyses show the Xpert MTB/RIF assay has high sensitivity and specificity for detecting rifampicin resistance. While a major improvement, the Xpert MTB/RIF assay is still being evaluated for use with extra-pulmonary samples which typically yield lower sensitivity. Rapid molecular diagnostics are transforming tuberculosis diagnosis and treatment monitoring.
Antimicrobial resistance for clinicians
Slide from WHO CME ITALIAN COURSE
Antimicrobial resistance for clinicians
Core competencies for antimicrobial prescribing:
Understands the patient and the patient’s clinical needs
Understands treatment options and how they support the
patient’s clinical needs
Works in partnership with the patient and other healthcare
professionals to develop and implement a treatment plan
Communicates the treatment plan and its rationale clearly to
the patient and other health professionals
Monitors and reviews the patient’s response to treatment
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
The document discusses the manufacturing process for COVID-19 vaccines. It describes the traditional vaccine development process which uses weakened pathogens versus the novel mRNA vaccine process used for COVID-19 vaccines which uses genetic code to produce antigens. The manufacturing process for vaccines involves fermentation, purification, formulation, filling and packaging. Challenges in developing COVID-19 vaccines include limited worldwide distribution due to cold chain requirements, lack of long term safety and efficacy data for novel mRNA vaccines, and ensuring proper vaccine administration to stimulate immunity.
Re-purposing ILRI labs to support national COVID-19 testing in Kenya
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
Recent advances in malaria
This document summarizes recent advances in malaria diagnosis, treatment, vaccines, and elimination efforts. It describes new diagnostic techniques like rapid diagnostic tests and molecular methods like PCR. It outlines recent treatment advances like new artemisinin-based combination therapies and injectable artesunate for severe malaria. It discusses the RTS,S malaria vaccine and new highly effective vaccine candidates in clinical trials. It also summarizes global strategies and targets for malaria elimination by 2030 through efforts like the WHO Global Malaria Programme, genetic research with MalariaGEN, and novel approaches like gene drive modified mosquitoes to reduce disease transmission.
SUPERBUGS , NEW HOPE NEW ANTIBIOTICS
This document summarizes new and emerging antibiotic treatments for multi-drug resistant bacteria, or "superbugs". It discusses several new classes of antibiotics targeting both Gram-positive and Gram-negative bacteria, including new cephalosporins, lipoglycopeptides, lipopeptides, streptogramins, carbapenems, and glycylcyclines. Concerns are raised about increasing antibiotic resistance and the lack of new antibiotic development, as well as the need to target emerging threats from multi-drug resistant Gram-negative bacteria.
MDR-TB
This document discusses multi-drug resistant tuberculosis (MDR TB). It begins with an introduction to TB and definitions of key terms like MDR and XDR TB. It then describes first and second line anti-TB drugs, mechanisms of drug resistance, and factors contributing to acquired resistance. The document outlines methods for diagnosing drug resistance including genetic detection and drug sensitivity testing. It concludes with a brief overview of treatment approaches for MDR TB.
Vish Nene - Building back better: How can public food and agricultural resear...
Vish Nene - Building back better: How can public food and agricultural resear...International Food Policy Research Institute (IFPRI)
POLICY SEMINAR
Virtual Event - Building back better: How can public food and agricultural research institutions be strengthened and rebuilt after the COVID-19 pandemic?
Co-Organized by IFPRI and the International Consortium on Applied Bioeconomic Research (ICABR)
FEB 2, 2021 - 09:30 AM TO 11:00 AM ESTWhat's hot (20)
Ebola virus disease in the democratic republic of Congo{
Ebola virus disease in the democratic republic of Congo{
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Re-purposing ILRI labs to support national COVID-19 testing in Kenya
Re-purposing ILRI labs to support national COVID-19 testing in Kenya
Vish Nene - Building back better: How can public food and agricultural resear...
Vish Nene - Building back better: How can public food and agricultural resear...
Similar to The Volente Difference
Antibiotic stewardship by dr praman
1) Antimicrobial stewardship programs aim to optimize antibiotic use and prevent resistance by coordinating actions to improve prescribing. They promote appropriate use through guidelines, education, and monitoring of antibiotic use and outcomes.
2) In NICUs, antimicrobial stewardship faces unique challenges due to non-specific signs of infection in neonates and difficulties obtaining cultures. Programs seek to minimize broad-spectrum antibiotic exposure and duration to reduce resistance and side effects.
3) Effective strategies for neonatal antimicrobial stewardship include developing unit-specific treatment guidelines, prospectively auditing antibiotic use, educating providers, streamlining therapy based on culture results, and implementing bundles to prevent infections.
Antimicrobial Stewardship ,Heba Abdallatif,BCPS
The document provides an overview of antimicrobial stewardship programs and antibiotic resistance. It discusses how antibiotic overuse has led to increased resistance [1]. Antimicrobial stewardship programs aim to optimize antibiotic use and slow resistance through coordinated actions [2]. The core elements of effective programs include leadership commitment, accountability, drug expertise, tracking antibiotic use and resistance, reporting on improvement efforts, and education [3]. Targeted strategies are needed given the unique challenges of prescribing antibiotics for neonatal intensive care patients. Bundles of evidence-based practices can help reduce healthcare-associated infections like CLABSIs in the NICU.
AMR.pptx
This document discusses antimicrobial resistance (AMR) and strategies for combating it. It begins by defining AMR and explaining that microorganisms can develop resistance to multiple antimicrobial agents, becoming "superbugs." It then discusses the global toll of AMR, listing bacteria identified by the CDC as urgent, serious, or concerning threats. The document emphasizes the need for antimicrobial stewardship programs in healthcare facilities to optimize antibiotic use and reduce resistance. It outlines components of stewardship programs like developing treatment guidelines, monitoring antibiotic use and resistance trends, and improving prescribing and de-escalation of therapy. The goal of stewardship is to use the right drug, for the right person, for the right duration. The document stresses
Antibiotics treatment & management
This document discusses guidelines for antibiotic treatment and management. It covers factors like selecting initial empiric therapy based on the infection type (mono vs polymicrobial), choosing agents based on likely pathogens, and tailoring therapy based on host factors. It recommends narrowing coverage once cultures identify pathogens. The optimal duration depends on the infection site but is typically 3-5 days for most infections. It advises converting IV therapy to oral when possible for safety and earlier discharge. Prolonged or excessive antibiotic use should be avoided to prevent resistance.
9 nosocomial pneumonia combating MDROs
Brief review of treatment of nosocomial pneumonia, with emphasis on the problem of multi- drug resistant organisms
Antibiotic usage in icu
This document discusses antibiotic usage guidelines in the ICU. It outlines principles for prescribing antibiotics such as sending appropriate cultures and following hospital antibiotic policies. It also describes strategies to optimize antibiotic use like patient risk stratification, de-escalation therapy, and implementing an antibiotic stewardship program. Common ICU infections like ventilator-associated pneumonia, urosepsis, and catheter-related bloodstream infections are reviewed along with treatment approaches and preventive measures.
Growing antimicrobial resistance – meeting the challenges
Growing antimicrobial resistance poses a serious threat as many bacteria are now resistant to existing antibiotics. This could lead to a "post-antibiotic era" with high mortality from infectious diseases. Rational antibiotic use at all levels is needed to slow resistance. Prompt diagnosis and targeted treatment are important, as is continuing research to develop new antibiotics. Improving hygiene, immunization rates, and antibiotic stewardship can help address this looming crisis.
12 PRINCIPLES OF ANTIBIOTIC THERAPY seminar 12.pptx
This PowerPoint presentation offers a concise yet technical overview of antibiotic therapy. Dive into antibiotic mechanisms, classifications, indications, and prudent use. Master essential aspects of antibiotic therapy for informed clinical decision-making.
1. Guidelines for the rational use of antibiotics and.pptx
Guidelines for the rational use of antibiotics and surgical prophylaxis provide definitions and guidelines around antibiotic use for surgery. They discuss defining surgery and why antibiotics are needed, risk factors that promote infection, classifying surgical wounds, and goals of antibiotic prophylaxis including reducing surgical site infections. The guidelines provide recommendations on antibiotic selection, timing of administration before and after surgery, and dosing to effectively prevent infections while minimizing antibiotic resistance and costs.
Antibiotic use in surgery
Antibiotics are used against a wide range of pathogens and are very important in preventing and treating infections. The use of appropriate choice of antibiotics, dose and enforcing compliance is important in patient's care and preventing drug resistance.
Guidelines for antibiotic use in icu
The document provides guidelines for antibiotic use in the ICU, including recommendations for empirical antibiotic choice, duration of therapy, and risk factors for multidrug-resistant pathogens. Key points addressed include empirically covering likely organisms like Staphylococcus aureus and Pseudomonas in severe CAP and HAP/VAP. Combination therapy and shorter courses are suggested when possible to reduce antibiotic resistance. Lower respiratory tract cultures should be obtained before but not delay treatment, and help determine if therapy can be stopped for negative cultures.
Acs0815 Antibiotics
The document discusses antibiotic therapy for surgical patients. It covers general principles of antimicrobial therapy including empirical therapy and laboratory tests to determine antibiotic susceptibility. It also discusses factors that influence antibiotic treatment such as route of administration, host factors like pregnancy, and advanced age. Finally, it provides guidelines for selecting antibiotics for common surgical infections like intra-abdominal infections.
ANTIBIOTIC STEWARDSHIP MEANS :USE OF THE RIGHT PATIENT,AT THE RIGHT TIME WITH...
use of the right antimicrobial, for right patient, at the right time, with right dose, right route, and frequency, causing the least harm to the patients and future patients as per CDC.
Refers to the coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regime, dose, duration of therapy, and route of administration[IDSA]
Antibiotic resistances
This document discusses antibiotic resistance as a major public health challenge. It notes that at least 2.8 million antibiotic-resistant infections occur in the US each year, resulting in over 35,000 deaths. Antibiotic resistance develops when bacteria evolve and gain the ability to defeat drugs designed to kill them. This makes infections harder to treat and requires more costly and toxic alternatives. The brief history provided shows how bacteria developed resistance soon after the introduction of early antibiotics like penicillin. It also outlines some of the major antibiotic-resistant bacteria according to the CDC's 2019 threats report and strategies to curb further resistance through judicious antibiotic use and developing new drugs.
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
The United States healthcare system has a serious infectious disease management problem. The antibiotic resistance crisis is widespread, serious, costly, and deadly. Delays in pathogen identification lead to poor clinical outcomes, including increased mortality risk. And, optimally managing outbreaks is critical to health systems whose reimbursement is tied to the health of a population, such as ACOs.
Eleanor Herriman, MD, MBA, Chief Medical Informatics Officer at Viewics led an informative panel discussion with industry leaders on the issues surrounding the infectious disease management crisis. Margret Oethinger, MD, Ph.D., Medical Director of Providence Health & Services, and Susan E. Sharp, Ph.D., DABMM, FAAM, Regional Director of Microbiology and the Molecular Infectious Disease Laboratories, Department of Pathology, Kaiser Permanente and President-Elect, American Society for Microbiology cover the current state of infectious disease management in the U.S., and what can be done to improve it.
You’ll learn about:
• The magnitude of the U.S. health system’s infectious disease management problem
• The most serious concerns and trends for healthcare institutions and communities across the nation
• The most promising solutions to health systems’ most urgent infectious disease management challenges
MDR Pathogens: The Nightmare of Intensivists
Lecture presented at the Egyptian African Critical care Summit, the leading critical care and emergency medicine event in Egypt
Antimicrobial Stewardship and Applications to Common Infections
Justin Kosar BSc., BSP
Lead – Antimicrobial Stewardship Pharmacist
Saskatoon Health Region
&
Lynette Kosar BSP, MSc
RxFiles Academic Detailing Program
Infection Control and Antibiotic resistance
This document discusses antimicrobial resistance and strategies to address it. It notes that antibiotic overuse has led to many resistant infections worldwide. To combat this, the WHO advocates a coordinated, multi-sector response including prudent antibiotic use, infection control, surveillance, and new drug development. Key strategies to reduce resistant infections in healthcare facilities include antibiotic stewardship programs, hand hygiene, isolation precautions, and developing treatment guidelines based on local resistance patterns.
Hospital Presentation
Advanced Next Generation DNA sequencing can more accurately diagnose infections by identifying bacteria, fungi, and viruses compared to traditional culture techniques. This allows for better treatment decisions. PathoGenius Laboratory uses Next Generation Sequencing to identify microbes in samples, providing physicians with diagnostic results to inform customized treatment. Previous methods of relying only on culture were found to significantly underrepresent the microbes present. Molecular diagnostic techniques provide more comprehensive information about biofilms and chronic infections compared to traditional approaches.
Similar to The Volente Difference (20)
Growing antimicrobial resistance – meeting the challenges
Growing antimicrobial resistance – meeting the challenges
12 PRINCIPLES OF ANTIBIOTIC THERAPY seminar 12.pptx
12 PRINCIPLES OF ANTIBIOTIC THERAPY seminar 12.pptx
1. Guidelines for the rational use of antibiotics and.pptx
1. Guidelines for the rational use of antibiotics and.pptx
ANTIBIOTIC STEWARDSHIP MEANS :USE OF THE RIGHT PATIENT,AT THE RIGHT TIME WITH...
ANTIBIOTIC STEWARDSHIP MEANS :USE OF THE RIGHT PATIENT,AT THE RIGHT TIME WITH...
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
Tackling the U.S. Healthcare System’s Infectious Disease Management Problem
Antimicrobial Stewardship and Applications to Common Infections
Antimicrobial Stewardship and Applications to Common Infections
Recently uploaded
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
Air Ambulance Services In Rewa works in close coordination with ground-based emergency services, including local Emergency Medical Services, fire departments, and law enforcement agencies.
More@: https://tinyurl.com/2shrryhx
More@: https://tinyurl.com/5n8h3wp8
Monopoly PCD Pharma Franchise in Tripura
Our company incorporates various drug formulations covering pharma tablets, syrups, capsules, gels, sachets, ointments, creams, injectables.
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
UoA毕业证学历书【微信95270640】办文凭{昆士兰科技大学毕业证}Q微Q微信95270640UoA毕业证书成绩单/学历认证UoA Diploma未毕业、挂科怎么办？+QQ微信：Q微信95270640-大学Offer（申请大学）、成绩单（申请考研）、语言证书、在读证明、使馆公证、办真实留信网认证、真实大使馆认证、学历认证
办理国外昆士兰科技大学毕业证书 #成绩单改成绩 #教育部学历学位认证 #毕业证认证 #留服认证 #使馆认证（留学回国人员证明） #（证）等
真实教育部认证教育部存档中国教育部留学服务中心认证（即教育部留服认证）网站100%可查.
真实使馆认证（即留学人员回国证明）使馆存档可通过大使馆查询确认.
留信网认证国家专业人才认证中心颁发入库证书留信网永久存档可查.
昆士兰科技大学昆士兰科技大学毕业证文凭证书毕业证 #成绩单等全套材料从防伪到印刷从水印到钢印烫金跟学校原版100%相同.
国际留学归国服务中心：实体公司注册经营行业标杆精益求精！
国外毕业证学位证成绩单办理流程：
1客户提供办理昆士兰科技大学昆士兰科技大学毕业证文凭证书信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询）；
2开始安排制作昆士兰科技大学毕业证成绩单电子图；
3昆士兰科技大学毕业证成绩单电子版做好以后发送给您确认；
4昆士兰科技大学毕业证成绩单电子版您确认信息无误之后安排制作成品；
5昆士兰科技大学成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快递邮寄昆士兰科技大学昆士兰科技大学毕业证文凭证书）。闷不乐的样子父亲特意带山娃去找三楼房东家的儿子小伍玩小伍比山娃小一岁虎头虎脑的很霸气父亲让山娃跟小伍去夏令营听课山娃很高兴夏令营就设在附近一所小学山娃发现那所小学比自己的学校更大更美操场上还铺有塑胶跑道呢里面很多小朋友一班一班的快快乐乐原来城里娃都藏这儿来了怪不得平时见不到他们山娃恍然大悟起来吹拉弹唱琴棋书画山娃都不懂却什么都想学山娃怨自己太笨什么都不会斟酌再三山娃终于选定了学美术当听说每月要交感
Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...rightmanforbloodline
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressedDigital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
FACIAL NERVE
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
Research, Monitoring and Evaluation, in Public Health
This is a presentation on the overview of the role of monitoring and evaluation in public health. It describes the various components and how a robust M&E system can possitively impact the results or effectiveness of a public health intervention.
DAHL APPROACH a novel technique to raise bite
dahl approach is alternative techniue to raise bite with direct restorations
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Know Latest Hiranandani Hospital Powai News.pdf
As Mumbai's premier kidney transplant and donation center, L H Hiranandani Hospital Powai is not just a medical facility; it's a beacon of hope where cutting-edge science meets compassionate care, transforming lives and redefining the standards of kidney health in India.
nursing management of patient with Empyema ppt
prepared by Prof. BLESSY THOMAS, SPN
Empyema is a disease of respiratory system It is defines as the accumulation of thick, purulent fluid within the pleural space, often with fibrin development.
Empyema is also called pyothorax or purulent pleuritis.
It’s a condition in which pus gathers in the area between the lungs and the inner surface of the chest wall. This area is known as the pleural space.
Pus is a fluid that’s filled with immune cells, dead cells, and bacteria.
Pus in the pleural space can’t be coughed out. Instead, it needs to be drained by a needle or surgery.
Empyema usually develops after pneumonia, which is an infection of the lung tissue. it is mainly caused due in infectious micro-organisms. It can be treated with medications and other measures.
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...The Lifesciences Magazine
The cyclothymia test is a pivotal tool in the diagnostic process. It helps clinicians assess the presence and severity of symptoms associated with cyclothymia.05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
Clinical audit on pain management done at peripheral health centre
English Drug and Alcohol Commissioners June 2024.pptx
Presentation made by Mat Southwell to the Harm Reduction Working Group of the English Drug and Alcohol Commissioners. Discuss stimulants, OAMT, NSP coverage and community-led approach to DCRs. Focussing on active drug user perspectives and interests
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
PRESSURE INJURY CARE AND MANAGEMENT FOR HCW
Cme on pressure injury care.
Credit to : PPP Abdul Manan Bin Othman.
UNIT PERKEMBANGAN PROFESYEN PPP
BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
Discover the Perfect Way to Relax - Malayali Kerala Spa Ajman
Malayali Kerala Spa in Ajman, one among the top rated massage centre in ajman, welcomes you to experience high quality massage services from massage staffs from all ove rthe world! Being the best spa massage service providers, we take pride in offering traditional massage services of different countries, like
Indian Massage, Kerala Massage, Thai Massage, Pakistani Massage, Russian Massage etc
If you are seeking relaxation, pain relief, or wellness experience, our ajman spa is here for your unique needs and concerns. The services of our experienced therapists, and personalized attention will ensure that each visit will be memorable for you.
Book your appointment today and let us take you to a world of serenity and self-care. Because you deserves the best.
Luxury Massage Experience at Affordable Rate - Malayali Kerala Spa Ajman
At Malayali Kerala Spa Ajman we providing the top quality massage services for our customers.
Our massage center prioritizes efficiency to ensure a quality massage experience for our clients at Malayali Kerala Spa Ajman. We offer a convenient appointment system and precise massage services.
Reach us at Villa No 7, Near Ammar Bin Yasir Street Al Rashidiya 2 - Ajman - United Arab Emirates.
Phone : +971 529818279
The Importance of Black Women Understanding the Chemicals in Their Personal C...
Certain chemicals, such as phthalates and parabens, can disrupt the body's hormones and have significant effects on health. According to data, hormone-related health issues such as uterine fibroids, infertility, early puberty and more aggressive forms of breast and endometrial cancers disproportionately affect Black women. Our guest speaker, Jasmine A. McDonald, PhD, an Assistant Professor in the Department of Epidemiology at Columbia University in New York City, discusses the scientific reasons why Black women should pay attention to specific chemicals in their personal care products, like hair care, and ways to minimize their exposure.
Recently uploaded (20)
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
Faridkot ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Faridkot
Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Research, Monitoring and Evaluation, in Public Health
Research, Monitoring and Evaluation, in Public Health
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...
English Drug and Alcohol Commissioners June 2024.pptx
English Drug and Alcohol Commissioners June 2024.pptx
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Discover the Perfect Way to Relax - Malayali Kerala Spa Ajman
Discover the Perfect Way to Relax - Malayali Kerala Spa Ajman
Luxury Massage Experience at Affordable Rate - Malayali Kerala Spa Ajman
Luxury Massage Experience at Affordable Rate - Malayali Kerala Spa Ajman
The Importance of Black Women Understanding the Chemicals in Their Personal C...
The Importance of Black Women Understanding the Chemicals in Their Personal C...
The Volente Difference
- 2. BENEFITS OF OUR PANELS
- 3. RESPIRATORY PATHOGEN PANEL (RPP) • SIMPLICITY OF A SINGLE SPECIMEN • NEXT DAY RESULTS WITH OPTIONAL ANTIBIOTIC RESISTANCE AND RX GUIDANCE • CO-DETECTION OF PATHOGENS WITH CONCENTRATIONS THAT INDICATE MULTIPLE PATHOGENS AS A CAUSE OF THE INFECTION • KNOW DEFINITIVELY IF THE CAUSATIVE PATHOGEN(S) IS A VIRUS, BACTERIA, OR BOTH • ANTIBIOTIC RESISTANCE DETECTED ON A GENETIC LEVEL, ALLOWING THE PROVIDER TO PREPARE AN ANTIBIOTIC CLASS AVOIDANCE STRATEGY Pg. 1
- 4. GASTROINTESTINAL • GENERAL SWAB COLLECTION. NO FECAL COLLECTION REQUIRED • 22 TARGETS FROM SINGLE SPECIMEN • DETECTS DIFFICULT TO CULTURE PATHOGENS • MULTIPLE BACTERIA TARGETED WITH RESISTANCE MECHANISMS: WHEN COMPLIMENTED WITH OUR ANTIBIOTIC RESISTANCE PANEL, APPROPRIATE ANTIBIOTIC THERAPY AVAILABLE “NEXT DAY” • REDUCE UNNECESSARY PRESCRIBING OF BROAD SPECTRUM ANTIBIOTICS • AT THE HEIGHT OF SWIMMING SEASON, NOROVIRUS IS PREVALENT IN THE PEDIATRIC COMMUNITY AS CHILDREN SWIM IN LAKES, RIVERS, AND SWIMMING POOLS WHERE THE VIRUS IS EASILY SPREAD Pg. 2
- 5. URINARY TRACT INFECTIONS AND SEXUALLY TRANSMITTED INFECTIONS • A SINGLE URINE SPECIMEN TARGETS 20 PATHOGENS FOUND TO CAUSE URINARY TRACT INFECTIONS AND SEXUALLY TRANSMITTED DISEASES • SYMPTOMATIC WOMEN CAN VISIT THEIR CLINIC AND A NURSE CAN QUICKLY COLLECT A STANDARD URINE SPECIMEN. DEFINITIVE RESULTS ARE AVAILABLE THE FOLLOWING DAY • UTI’S ARE PREVALENT IN LONG TERM CARE FACILITIES; PRIMARILY AMONG PATIENTS WITH URINARY CATHETERS • UTI’S ARE COMMON HEALTHCARE ACQUIRED INFECTIONS (HAI’S) • OUR TEAM WILL ASSIST IMPLEMENTING OUR TECHNOLOGY INTO YOUR ANTIMICROBIAL STEWARDSHIP PROGRAM Pg. 3
- 6. WOUND CARE • GENERAL SWAB OF THE WOUND YEILDS NEXT DAY RESULTS WITH 99.8% SENSITIVITY & SPECIFICITY • E. COLI, METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), VANCOMYCIN RESISTANT ENTEROCOCCI, ALONG WITH SEVERAL ADDITIONAL ANTIBIOTIC RESISTANT STRAINS CAN BE DETECTED WHEN ACCOMPANIED WITH OUR ANTIBIOTIC RESISTANCE PANEL • DIFFICULT TO TREAT WOUND INFECTIONS ARE OFTEN CAUSED BY RESISTANT STRAINS OF BACTERIA THAT CAN BE IDENTIFIED AND, PLACED IN THE HANDS OF OUR PHARMACY TEAM, CAN DEMONSTRATE IMPROVED PATIENT OUTCOMES WHEN PLACED ON AN APPROPRIATE TREATMENT PLAN Pg. 4
- 7. Leaders In Molecular Diagnostics THE LEADER IN PROVIDING TRULY ACTIONABLE, PATIENT-CENTERED REPORTING INCLUDING OUR UNIQUE PHARMACY MEDICATION REVIEW REPORT Pg. 5